GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a ...

Shares of GH Research climbed after the company said it would provide data from a trial of its drug for treatment-resistant depression. The stock rose 5.2%, to $11.15, in after-hours trading on Friday ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Rachel Norris, MD ...

A bipartisan group of legislators have introduced a bill at the roundhouse that would allow New Mexicans to take psychedelic ...

Beyond called off its $40 million investment deal with The Container Store. The parent company of Bed, Bath and Beyond in November cast doubt on the deal, expressing concerns the specialty retailer ...

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression. The hallucinogenic drug is an option when traditional treatment isn’t ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Enveric Biosciences receives notice of allowance from USPTO for its drug candidate EB-003 to treat mental health disorders: Cambridge, Massachusetts Saturday, February 1, 2025, 13 ...

The vagus nerve is a key part of the parasympathetic nervous system influencing bodily functions like heart rate digestion ...

The one-two punch sent newly consolidated shares tumbling despite progress on its non-hallucinogenic depression treatment.

The potential legalization of magic mushrooms is heading to Olympia next week as state lawmakers prepare to hear testimony on two bills ...